NCT05371353View on ClinicalTrials.gov

Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

RecruitingOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

May 14, 2022

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
HPV InfectionsCervical Cancer Stage IIaVaginal CancerGenital WartCIN1CIN2CIN3
Trial Locations (2)

Unknown

RECRUITING

Yangchun Center For Disease Prevention And Control, Yangchun

RECRUITING

Center for Disease Control and Prevention, Mianyang

All Listed Sponsors
lead

Shanghai Bovax Biotechnology Co., Ltd.

INDUSTRY